KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Leases (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Leases for 7 consecutive years, with $26.7 million as the latest value for Q4 2025.

  • Quarterly Leases rose 9.13% to $26.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.7 million through Dec 2025, up 9.13% year-over-year, with the annual reading at $26.7 million for FY2025, 9.13% up from the prior year.
  • Leases for Q4 2025 was $26.7 million at Supernus Pharmaceuticals, down from $28.8 million in the prior quarter.
  • The five-year high for Leases was $35.4 million in Q4 2021, with the low at $21.9 million in Q2 2025.
  • Average Leases over 5 years is $28.5 million, with a median of $29.0 million recorded in 2023.
  • The sharpest move saw Leases skyrocketed 55.47% in 2021, then decreased 18.27% in 2022.
  • Over 5 years, Leases stood at $35.4 million in 2021, then dropped by 18.27% to $28.9 million in 2022, then rose by 0.31% to $29.0 million in 2023, then decreased by 15.58% to $24.5 million in 2024, then grew by 9.13% to $26.7 million in 2025.
  • According to Business Quant data, Leases over the past three periods came in at $26.7 million, $28.8 million, and $21.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.